Concurrent heroin self-administration and intracranial self-stimulation in rats

https://doi.org/10.1016/0091-3057(85)90079-6Get rights and content

Abstract

In a two-lever testing chamber, rats lever pressed for lateral hypothalamic brain stimulation or intravenous heroin reinforces on a concurrent FR1 FR1 schedule of reinforcement. Responding for stimulation did not alter the rate of heroin self-administration, and responding for heroin caused increased responding for stimulation. Discontinuing heroin injections, or administering 3 mg/kg of naloxone, disrupted responding for both reinforcers, while changing the unit dose of heroin did not appreciably affect response rates for stimulation. This experiment demonstrates that rats are able to lever press during the period between successive self-administered heroin infusions, suggesting that the pausing normally seen between infusions is not due to debilitation, stereotyping, or sedation.

References (18)

There are more references available in the full text version of this article.

Cited by (12)

  • Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug

    2018, Pharmacology Biochemistry and Behavior
    Citation Excerpt :

    Sullivan et al. (2006) found that naltrexone, when administered chronically as a depot implant, reduced heroin choice in humans. Similar findings have been reported with the shorter-acting opioid antagonist, naloxone, in rats (Gerber et al., 1985), NHPs (Negus, 2006), and humans (when combined with buprenorphine; Comer et al., 2005). It should be noted, however, that for opioid abusers, the effects of mu-opioid antagonists can vary widely depending on the current state of the patient on a dependence continuum.

  • Insights from Preclinical Choice Models on Treating Drug Addiction

    2017, Trends in Pharmacological Sciences
    Citation Excerpt :

    To date, preclinical drug versus nondrug choice procedures have been established for the abused drugs cocaine [20–22], methamphetamine [23,24], 3,4-methylenedioxymethamphetamine [25], heroin [26,27], remifentanil [28], secobarbital and chlordiazepoxide [29], and nicotine [30] in either nonhuman primates or rats. With the exception of one heroin versus electrical brain stimulation choice study [31], all other preclinical drug versus nondrug choice procedures have used some food variant as the alternative nondrug reinforcer. This body of literature has suggested three main findings.

  • Medications development for treatment of opioid use disorder

    2021, Cold Spring Harbor Perspectives in Medicine
  • Medications development for opioid abuse

    2013, Cold Spring Harbor Perspectives in Medicine
View all citing articles on Scopus
View full text